Trial · NCT01786512
Results by group133
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 133
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 193 | Standard Deviation 58.8 | ng/mL | |
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 201 | Standard Deviation 94.4 | ng/mL | |
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | 171 | Standard Deviation 53.8 | ng/mL | |
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | 492 | Standard Deviation 115 | ng/mL | |
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | 502 | Standard Deviation 138 | ng/mL | |
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | 601 | Standard Deviation 204 | ng/mL | |
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 3.9 | Standard Deviation 4.4 | hours | |
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 2.0 | Standard Deviation 1.2 | hours | |
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | 4.2 | Standard Deviation 1.9 | hours | |
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | 2.6 | Standard Deviation 2.4 | hours | |
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | 2.2 | Standard Deviation 1.8 | hours | |
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | 4.6 | Standard Deviation 2.3 | hours | |
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 157 | Standard Deviation 63.7 | ng/mL | |
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 137 | Standard Deviation 56.8 | ng/mL | |
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | 134 | Standard Deviation 54.7 | ng/mL | |
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | 376 | Standard Deviation 170 | ng/mL | |
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | 395 | Standard Deviation 108 | ng/mL | |
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | 476 | Standard Deviation 234 | ng/mL | |
| Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 2030 | Standard Deviation 658 | ng*hr/mL | |
| Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 2000 | Standard Deviation 1020 | ng*hr/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01786512/results